

Register Competence Network Parkinson's Disease

<https://neurodegenerationresearch.eu/survey/register-competence-network-parkinsons-disease/>

Title of the register

Register Competence Network Parkinson's Disease

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Wolfgang

Name of Principal Investigator - Last name

Oertel

Address of institution -Institution

Philipps University Marburg

Address of institution - Street address

Baldingerstraße

Address of institution - City

Marburg

Address of institution - Postcode

35039

Country

Germany

Website

www.kompetenznetz-parkinson.de

Contact email

gisela.antony@med.uni-marburg.de

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Parkinson's disease

Q2. In a single sentence, what is the stated aim of your register?

Describe Parkinson patients in standardized follow-ups

Q2b. What distinguishes this register from other disease registers?

Q3a. i) Number of publications that involve use of your register to date

0

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available?

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the register

Q4a. Study criteria: what is the age range of participants? Age in years: from

18

Q4a. Study criteria: what is the age range of participants? Age in years: to

until death

Q4b. Study criteria: what are the inclusion criteria?

idiopathic PD, MSA, PSP, healthy controls

Q4c. Study criteria: what are the exclusion criteria?

no exclusion criteria specified

Q5. What is the size of the register (i.e. how many patients have been enrolled)?

Q6a. Please describe what measures are used to characterise participants

demographics, diagnosis, symptomatic, medical, psychological and psychiatric examination, concomitant medication and diseases, medication, imaging, optional assessments: UPDRS, PDQ-39, MADRS, MMSE

Q6b. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If YES, please describe

Q7a. i) Is the register of fixed duration?

Yes

Q7a. ii) Please enter the data collection start date

01/01/2001

Q7a. iii) Please enter the data collection end date

Q7b. Could you provide some information about the data collection for this register?

Data collection ongoing|Data analysis ongoing

Q8. Funding of the register - How is the register funded?

Q8. Funding of the register - Is this funding expected to continue

Q8. Funding of the register - If so, for how long (months)?

Q9. Could you provide information about data sweeping? - How many data sweeps have taken place?

Q9. Could you provide information about data sweeping? - When was the most recent data sweep?

Q9. Could you provide information about data sweeping? - When is the next data sweep?

Q9. Could you provide information about data sweeping? - How many more data sweeps are planned on current funding? e.g 0,1,2.....

Q9. Could you provide information about data sweeping? -How many more data sweeps are planned in total (with funding and with funding yet to be secured) e.g. 0,1,2...

Q10. Is the clinical (phenotypic) information that is held in the register from patients and other participants such as family members:

Q11. Is there a limit on the number of studies that can be based on this set of patients?

If YES, please give details

Q12a. Please give information on the format and availability of data stored in a database (1)

% Available

Q12a. Please give information on the format and availability of data stored in a database (2)

% Available

Q12a. Please give information on the format and availability of data stored in a database (3)

% Available

Q12a. Please give information on the format and availability of data stored in a database (4)

% Available

Q12a. Please give information on the format and availability of data stored in a database (5)

% Available

Please specify language used

Q12b. Please give information on how data is held as individual records (1)

% Available

Q12b. Please give information on how data is held as individual records (2)

% Available

Q12b. Please give information on how data is held as individual records (3)

% Available

Q12b. Please give information on how data is held as individual records (4)

% Available

Please specify language used

Q13a. Is data available to other groups?

Q13b. If data is available to other groups what is the access policy/mechanisms for access?

Other access mechanism|Researchers have to ask; data security committee must agree, according to patient agreement details

Q14. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

Q15a. Are tissues/samples/DNA available to other groups?

Yes

Q15b. i) If yes, please describe below:

Q15b. ii) In what form are tissues/samples/DNA supplied?

Q15b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q13b above)?

Q16a. Is information on biological characteristics available to other groups?

If available for a subset please specify number of patients and % of total cohort

Number of patients

% of total cohort

Q16b. If yes, is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q13b above)?

Yes

Types:

Disease Registers

Member States:

Germany

Diseases:

Parkinson's disease & PD-related disorders

Years:

2016

Database Categories:

N/A

Database Tags:

N/A